CNBC's Jim Cramer highlights Texas Instruments (TXN) for its operational strength, as the chipmaker navigates a challenging market with better-than-expected guidance and analyst optimism.
CNBC's Jim Cramer refrained from declaring a floor for Broadcom's stock amid mixed analyst sentiment and growing competition in the crucial AI semiconductor sector.
CNBC's Jim Cramer highlights supply constraints as the primary force behind Western Digital's stock surge, even as analysts raise price targets. The commentary links the storage maker's fortunes to broader semiconductor and AI trends.
As industry analysts warn of a critical NAND wafer shortage in 2026-2027, SanDisk's stock soars. Jim Cramer highlights the memory maker's positioning, with Mizuho and Benchmark raising price targets significantly on expectations of a 330% price spike.
China Life Insurance announces governance changes and a major investment partnership, highlighting a strategic pivot towards long-term, related-party investments amidst evolving regulatory landscapes in Asia's insurance sector.
Medtronic secures a key European regulatory nod for its latest pulsed field ablation catheter while deepening its collaboration with Mindray, signaling a strategic push into high-growth areas of cardiac care and ambulatory surgery.
Divergent analyst reports from Truist and Goldman Sachs on CCC Intelligent Solutions have cast a spotlight on the data firm's path to profitability, revealing deep-seated debates about its role in the auto insurance ecosystem and its ability to convert steady growth into sustained margins.
ARK Invest's founder capitalized on recent market weakness to increase holdings in three of her flagship disruptive innovation picks, signaling continued conviction despite sector volatility.
As the Bank of Canada holds rates steady, speculative capital is sifting through junior resource stocks. We examine three micro-caps—a driller, an explorer, and an oil hopeful—navigating unique challenges and opportunities in early 2026.
Meta Platforms is charting an unprecedented course in capital investment, with plans to spend up to $135 billion by 2026 to build the infrastructure for AI 'superintelligence.' The staggering sum highlights the scale of Big Tech's arms race and raises questions about long-term returns.
In its latest investor letter, David Einhorn's Greenlight Capital revealed it has sold its stake in HP Inc., redirecting capital towards AI-focused investments it believes offer superior risk-reward profiles amid the tech giant's recent struggles.
A fatal shark attack on a 13-year-old boy at a popular Brazilian beach has reignited concerns over coastal safety and led authorities to expand monitoring efforts along Pernambuco's coastline.
In its Q4 2025 letter, David Einhorn's Greenlight Capital revealed a new position in Antero Resources (AR), signaling a strategic move into the natural gas sector. The hedge fund's portfolio returned 8.5% for the quarter, outpacing the S&P 500.
South Africa has ordered Israel's deputy ambassador to leave the country, declaring him persona non grata in a significant diplomatic escalation reflecting Pretoria's strong stance on the war in Gaza.
David Einhorn's Greenlight Capital has closed its position in insurer Brighthouse Financial following a sale agreement, detailing the move in its latest investor letter. The hedge fund reported solid quarterly returns but continues to trail the broader market.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
The AI-as-a-Service (AIaaS) market is witnessing significant growth, fueled by cloud innovation and corporate demand for scalable AI solutions. While data privacy remains a hurdle, the integration of generative AI and tailored platforms is accelerating adoption across industries.
As Eli Lilly prepares to report its Q4 and full-year 2025 results on February 4th, investors are weighing whether the pharmaceutical giant's premium valuation leaves room for a positive surprise, or if the stock is priced for perfection.
Newly launched oral weight-loss drug Wegovy from Novo Nordisk recorded more than 26,000 U.S. prescriptions in its second full week, signaling robust early demand as competition with Eli Lilly intensifies.
Goldman Sachs downgrades iHeartMedia to Sell, warning that shifting audio consumption and ad trends threaten growth, even as the company's TikTok partnership aims to capture younger audiences.
